324JR, Associate Director, Program Management, Clinical Development

Job Code 324JR

Description

Fate is seeking an experienced Associate Director, Program Management for managing the clinical development and commercialization of Fate’s iProduct portfolio consisting of off-the-shelf cellular immunotherapies. Adhering to Fate Therapeutics standard procedures and processes, the successful candidate will be responsible for owning and achieving interim and final deliverables to support the clinical development life cycle according to timelines and corporate objectives. This individual will in part direct cross-functional teams to accomplish various tasks, proactively identify, resolve/mitigate and escalate risks and/or issues, and may be required to manage large and/or particularly complex, multifaceted clinical projects or programs and provide oversight to other members of the program management group. This is a full-time position located at our corporate headquarters in San Diego, CA reporting to the Director of Program Management.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 324JR.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.